NanoViricides Advances Oral NV-387 Against Bundibugyo Ebola After 88 Deaths
NNVC•NanoViricides highlights NV-387 as a broad-spectrum oral antiviral candidate that mimics sulfated proteoglycans to neutralize the Bundibugyo Ebola strain driving at least 88 deaths and 336 suspected cases across DRC and Uganda. Its room-temperature-stable gummies require no cold chain.
1. Bundibugyo Outbreak Overview
The Bundibugyo Ebola outbreak declared May 15, 2026 in Eastern DR Congo has produced at least 336 suspected cases and 88 deaths, with two infections confirmed in Uganda, prompting a Public Health Emergency declaration and US agencies to isolate and monitor exposed nationals.
2. NV-387 Mechanism and Advantages
NV-387 mimics sulfated proteoglycans to bind and destroy filoviruses at initial cell-attachment sites, reducing viral escape. Its oral gummy format dissolves naturally, is stable at room temperature and eliminates the need for cold chain and infusion infrastructure in remote regions.
3. Clinical Pipeline and Partnerships
NanoViricides holds a broad, exclusive sub-licensable license from TheraCour Pharma for its nanoviricide technology. NV-387 is in clinical development as a universal antiviral, with planned indications spanning respiratory viruses (RSV, COVID, influenza) and filovirus infections.
4. Commercial and Pandemic Preparedness Implications
If effective against the Bundibugyo strain, NV-387 could fill treatment gaps left by strain-specific vaccines and antibodies, offering a versatile countermeasure for all ebolaviruses. This could reshape pandemic preparedness strategies and unlock new revenue streams for NanoViricides.
